Patents by Inventor Hans-Georg KOPP

Hans-Georg KOPP has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RANKL-specific agent for treating metastatic disease
    Patent number: 12048744
    Abstract: The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: July 30, 2024
    Assignee: Probiocon GmbH
    Inventors: Helmut Salih, Ludger Grosse-Hovest, Andreas Herrmann, Hans-Georg Kopp, Stefanie Maurer
  • RANKL-SPECIFIC AGENT FOR TREATING METASTATIC DISEASE
    Publication number: 20210128722
    Abstract: The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.
    Type: Application
    Filed: September 17, 2020
    Publication date: May 6, 2021
    Inventors: Helmut SALIH, Ludger GROSSE-HOVEST, Andreas HERRMANN, Hans-Georg KOPP, Stefanie MAURER
  • RANKL-specific agent for treating metastatic disease
    Patent number: 10806786
    Abstract: The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: October 20, 2020
    Assignee: Probiocon GmbH
    Inventors: Helmut Salih, Ludger Grosse-Hovest, Andreas Herrmann, Hans-Georg Kopp, Stefanie Maurer
  • RANKL-SPECIFIC AGENT FOR TREATING METASTATIC DISEASE
    Publication number: 20170319687
    Abstract: The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.
    Type: Application
    Filed: November 12, 2015
    Publication date: November 9, 2017
    Applicant: Probiocon GmbH
    Inventors: Helmut SALIH, Ludger GROSSE-HOVEST, Andreas HERRMANN, Hans-Georg KOPP, Stefanie RAAB